
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
They are not the most common of dermatitis types that dermatologists typically see in their practices, but asteatotic dermatitis and neurodermatitis are driving some people to seek relief from their doctors.






